All In Biotech

Free tool

FAERS Monitor: Mitosol

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022572 or its brand name (Mitosol, Mitomycin). Reports on generic versions are filed under their own applications.

Reports

2,564

Serious

2,416

94% of reports

Hospitalization

857

Death reported

377

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • off label use364
  • diarrhoea152
  • nausea132
  • thrombocytopenia107
  • neutropenia106
  • drug ineffective101
  • disease progression98
  • pancytopenia93
  • vomiting89
  • fatigue78
  • death76
  • leukopenia74
  • febrile neutropenia71
  • pyrexia67
  • malignant neoplasm progression65

Reports by year received

View as table
YearReports
200467
200577
200686
200796
2008125
200979
201094
2011137
2012134
2013129
201495
2015115
201698
201787
2018127
2019160
2020152
2021126
202289
202374
2024133
2025177
2026107

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,595 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
pancytopeniaSignal9313.711.21,081
leukopeniaSignal7412.29.7747
febrile neutropeniaSignal718.87.0483
thrombocytopeniaSignal1077.96.5636
disease progressionSignal986.85.6481
neutropeniaSignal1066.45.3480
malignant neoplasm progressionSignal655.24.1218
off label useSignal3643.43.1644
diarrhoea1521.91.770
pyrexia671.61.314
vomiting891.61.317
nausea1321.41.213
fatigue780.80.73
death760.70.68
drug ineffective1010.60.523

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.